Formulation and Development of Newer Aripiprazole Immediate Release Tablets Kumar Poonguzhali Sathish1,*, Basak Subal Chandra1, Babu Sitty Manohar2 1Department of Pharmacy, Annamalai University, Chidambaram, 608002, Tamil Nadu, India 2Department of Pharmacology, SIMS College of Pharmacy, Guntur, 522001, Andhra Pradesh, India *Corresponding Author E-mail: poongi2007@gmail.com
Online published on 17 July, 2017. Abstract Aripiprazole is an antipsychotic medication, works by changing the actions of chemicals in the brain. It is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). In order to formulate a newer aripiprazole immediate release tablet of strength 30mg we evaluated the physical characteristics and the dissolution profile of the lab scale batch. The dissolution profile of the reference product and in house product was compared. The tablets from the lab scale batch were also subjected to accelerated stability studies. The results obtained were satisfactory and within the specified limits. In-vitro release profiles of the in-house product and reference product were similar. The lab scale batch tablets were found to be stable. Top Keywords Aripiprazole, schizophrenia, lab scale batch, accelerated stability study, immediate release tablets. Top |